Literature DB >> 7031185

Speech disorders of Parkinsonism: a review.

E M Critchley.   

Abstract

Study of the speech disorders of Parkinsonism provides a paradigm of the integration of phonation, articulation and language in the production of speech. The initial defect in the untreated patient is a failure to control respiration for the purpose of speech and there follows a forward progression of articulatory symptoms involving larynx, pharynx, tongue and finally lips. There is evidence that the integration of speech production is organised asymmetrically at thalamic level. Experimental or therapeutic lesions in the region of the inferior medial portion of ventro-lateral thalamus may influence the initiation, respiratory control, rate and prosody of speech. Higher language functions may also be involved in thalamic integration: different forms of anomia are reported with pulvinar and ventrolateral thalamic lesions and transient aphasia may follow stereotaxis. The results of treatment with levodopa indicates that neurotransmitter substances enhance the clarity, volume and persistence of phonation and the latency and smoothness of articulation. The improvement of speech performance is not necessarily in phase with locomotor changes. The dose-related dyskinetic effects of levodopa, which appear to have a physiological basis in observations previously made in post-encephalitic Parkinsonism, not only influence the prosody of speech with near-mutism, hesitancy and dysfluency but may affect work-finding ability and in instances of excitement (erethism) even involve the association of long-term memory with speech. In future, neurologists will need to examine more closely the role of neurotransmitters in speech production and formulation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7031185      PMCID: PMC491132          DOI: 10.1136/jnnp.44.9.751

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  36 in total

1.  Psychometric studies of verbal functions following thalamic lesions in humans.

Authors:  M Riklan; I S Cooper
Journal:  Brain Lang       Date:  1975-01       Impact factor: 2.381

2.  Language changes after neurosurgery for Parkinsonism.

Authors:  F L Darley; J R Brown; W M Swenson
Journal:  Brain Lang       Date:  1975-01       Impact factor: 2.381

3.  Dyspnea as a symptom in parkinson's syndrome.

Authors:  C A NUGENT; H W HARRIS; J COHN; C C SMITH; F H TYLER
Journal:  Am Rev Tuberc       Date:  1958-11

4.  Anterior chorodial artery ligation for involuntary movements.

Authors:  I S COOPER
Journal:  Science       Date:  1953-08-14       Impact factor: 47.728

5.  Amantadine in Parkinson's disease.

Authors:  P Millac; I Hasan; M L Espir; D G Slyfield
Journal:  Lancet       Date:  1970-02-28       Impact factor: 79.321

6.  Familial palilalia.

Authors:  F Boller; M Boller; G Denes; W H Timberlake; I Zieper; M Albert
Journal:  Neurology       Date:  1973-10       Impact factor: 9.910

7.  Speech representation in ventrolateral thalamus.

Authors:  G A Ojemann; A A Ward
Journal:  Brain       Date:  1971       Impact factor: 13.501

8.  Naturally occurring dyskinesias.

Authors:  E M Critchley
Journal:  Lancet       Date:  1970-11-21       Impact factor: 79.321

9.  Letter: Peak-dose dysphonia in parkinsonism.

Authors:  E M Critchley
Journal:  Lancet       Date:  1976-03-06       Impact factor: 79.321

10.  Prediction of short-term verbal memory disturbance after ventrolateral thalamotomy.

Authors:  G A Ojemann; K B Hoyenga; A A Ward
Journal:  J Neurosurg       Date:  1971-08       Impact factor: 5.115

View more
  16 in total

1.  Detection of Articulatory Deficits in Parkinson's Disease: Can Systematic Manipulations of Phonetic Complexity Help?

Authors:  Mili Kuruvilla-Dugdale; Mary Salazar; Anqing Zhang; Antje S Mefferd
Journal:  J Speech Lang Hear Res       Date:  2020-06-29       Impact factor: 2.297

2.  Acoustic analysis in the differentiation of Parkinson's disease and major depression.

Authors:  A J Flint; S E Black; I Campbell-Taylor; G F Gailey; C Levinton
Journal:  J Psycholinguist Res       Date:  1992-09

3.  The interpretation of dysprosody in patients with Parkinson's disease.

Authors:  J F Caekebeke; A Jennekens-Schinkel; M E van der Linden; O J Buruma; R A Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-02       Impact factor: 10.154

4.  The response of the apparent receptive speech disorder of Parkinsonism to speech therapy.

Authors:  D E Hartman; J H Abbs
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

5.  The "pacing board" in selected speech disorders of Parkinson's disease.

Authors:  A E Lang; V Fishbein
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-08       Impact factor: 10.154

Review 6.  Early Parkinson's disease: what is the best approach to treatment.

Authors:  A H Hristova; W C Koller
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

7.  Repetitive speech phenomena in Parkinson's disease.

Authors:  T Benke; C Hohenstein; W Poewe; B Butterworth
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

8.  Evaluation of the effects of deep brain stimulation of the subthalamic nucleus and levodopa treatment on parkinsonian voice using perturbation, nonlinear dynamic, and perceptual analysis.

Authors:  Xiao Ping Zhou; Victoria S Lee; Emily Q Wang; Jack J Jiang
Journal:  Folia Phoniatr Logop       Date:  2009-07-09       Impact factor: 0.849

9.  A data mining methodology for predicting early stage Parkinson's disease using non-invasive, high-dimensional gait sensor data.

Authors:  Conrad Tucker; Yixiang Han; Harriet Black Nembhard; Mechelle Lewis; Wang-Chien Lee; Nicholas W Sterling; Xuemei Huang
Journal:  IIE Trans Healthc Syst Eng       Date:  2015-11-20

10.  Lithium-induced improvement of myotonia: relevance of prostaglandin E1 blockade by lithium.

Authors:  J Backon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.